|
[Related PubMed/MEDLINE]
Total Number of Papers: 51
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Defining Diagnostic Criteria for Prostatic Ductal Adenocarcinoma at Multiparametric MRI. |
DAC, NPV, PPV |
| 2 |
2022 |
RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signatures. |
EMT, TCC |
| 3 |
2022 |
Serendipity for the intervention of COVID-19 and prostatic adenocarcinoma (PaC). |
--- |
| 4 |
2021 |
Ablation of Red Stable Transfected Claudin Expressing Canine Prostate Adenocarcinoma and Transitional Cell Carcinoma Cell Lines by C-CPE Gold-Nanoparticle-Mediated Laser Intervention. |
C-CPE, CLDN, GNOME-LP, SEM, TCC |
| 5 |
2021 |
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma. |
AR, DDR, DHT, mCRPC, PSA |
| 6 |
2021 |
Aptamer Probes Labeled with Lanthanide-Doped Carbon Nanodots Permit Dual-Modal Fluorescence and Mass Cytometric Imaging. |
FFPE, IFM, IMC, ROI |
| 7 |
2021 |
Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. |
AR, BRCA2, CDK12, IDC-P, NCOR2, PCa, TP53 |
| 8 |
2021 |
Comparative study of immunohistochemical expression of ERG and MAGI2 in prostatic carcinoma. |
DA, HGPIN, IHC, NPH |
| 9 |
2021 |
HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma. |
HOXB13, IHC, PC, PSA, pTNM, TFF3 |
| 10 |
2021 |
Optimizing the diagnosis and management of ductal prostate cancer. |
DAC |
| 11 |
2020 |
Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis. |
TCC |
| 12 |
2020 |
Delayed 68Ga-PSMA PET/CT Image-Guided Biopsy for Low-Grade Adenocarcinoma in Benign Prostatic Hyperplasia. |
--- |
| 13 |
2020 |
Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. |
ADT, DAC, MFS, OS, RP |
| 14 |
2020 |
Metal-Labeled Aptamers as Novel Nanoprobes for Imaging Mass Cytometry Analysis. |
167Er-DTPA, IMC, MAP |
| 15 |
2020 |
Metastatic prostate adenocarcinoma to cervical lymph nodes: an unusual diagnosis on fine-needle aspiration biopsy. |
FNAB |
| 16 |
2020 |
[Clinical features and epidemiological trend of prostate cancer in the Changsha area of Hunan Province: Analysis of 2 877 cases]. |
--- |
| 17 |
2016 |
Differential Immunohistochemical Profiles for Distinguishing Prostate Carcinoma and Urothelial Carcinoma. |
AMACR, GATA3, PAP, PSA, PSMA, UC |
| 18 |
2016 |
GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. |
ADT, CREB, NED, NEPC |
| 19 |
2016 |
Prostate cancer: from Gleason scoring to prognostic grade grouping. |
--- |
| 20 |
2016 |
Synchronous mantle cell lymphoma and prostate adenocarcinoma-is it just a coincidence? |
CHOP, LHRH, MCL, MSCT, PSA |
| 21 |
2015 |
A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells. |
AR, NED, NEPC, PCa |
| 22 |
2015 |
Structural study of endopelvic fascia in prostates of different weights. Anatomic study applied to radical prostatectomy. |
--- |
| 23 |
2014 |
Immunohistochemical differential diagnosis between urothelial carcinoma and prostate adenocarcinoma among Egyptian patients. |
MAC, NPH, TCC |
| 24 |
2013 |
A novel subtype of primary prostatic adenocarcinoma: A case report. |
PSA, UC |
| 25 |
2013 |
Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. |
DAC, PCDF |
| 26 |
2011 |
IGFBP2 as an immunohistochemical marker for prostatic adenocarcinoma. |
HGPIN, IGFBP2 |
| 27 |
2009 |
The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. |
CAD, CgA, NE, PC, PSA |
| 28 |
2009 |
Urothelial carcinoma and prostatic adenocarcinoma presenting as collision tumors. |
UC |
| 29 |
2008 |
Primary prostatic central zone adenocarcinoma. |
CZ, HGPIN |
| 30 |
2007 |
Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate. |
IT |
| 31 |
2007 |
Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. |
PSMA, UBC |
| 32 |
2007 |
Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases. |
CEA, CK20, CK7, FNAB, PAP, PSA |
| 33 |
2007 |
The 3-dimensional structure of isolated and small foci of prostatic adenocarcinoma: the morphologic relationship between prostatic adenocarcinoma and prostatic intraepithelial neoplasia. |
HGPIN, ISPAC |
| 34 |
2004 |
The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy. |
DVH |
| 35 |
2003 |
A simple technique for calculation of the volume of prostatic adenocarcinomas in radical prostatectomy specimens. |
BPH, GS, PZ, RP, TZ |
| 36 |
2003 |
Col IV and Fn distribution in prostatic adenocarcinoma and correlation of 67LR, MMP-9 and TIMP-1 expression with Gleason score. |
BM, BPH, Col IV, FN, MMP-9, TIMP-1 |
| 37 |
2002 |
High-dose rate brachytherapy of prostatic adenocarcinoma in combination with external beam radiotherapy a long-term follow-up of the first 50 patients at one center. |
--- |
| 38 |
2002 |
Identification of isolated and early prostatic adenocarcinoma in radical prostatectomy specimens with correlation to biopsy cores: clinical and pathogenetic significance. |
ISPAC, NTZ, TZ |
| 39 |
2002 |
Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. |
CK, PAP, PSA, TM, UC, UP |
| 40 |
2001 |
Primary and secondary prostatic adenocarcinoma of the urinary bladder. |
--- |
| 41 |
2001 |
Transitional zone and anterior peripheral zone of the prostate. A correlation of small-volume cancer in the biopsy cores and high psa with positive anterior margins in radical prostatectomy specimens. |
APZ, PPZ, RP, TZ |
| 42 |
2000 |
Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma. |
PSA, TRUS |
| 43 |
2000 |
Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. |
PSA, RR, RT-PCR |
| 44 |
1999 |
Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. |
BPH |
| 45 |
1998 |
[A case of poorly differentiated adenocarcinoma of prostate with neuroendocrine differentiation]. |
NE |
| 46 |
1997 |
Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. |
BBN, NP, PIN |
| 47 |
1996 |
Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. |
bp, CD44s |
| 48 |
1996 |
Immunohistochemical evaluation of type IV collagenase (72-kd metalloproteinase) in prostatic intraepithelial neoplasia. |
NP, PIN |
| 49 |
1996 |
[Significance of argyrophil staining for nucleolar organizer regions (AgNORs) to pathologic diagnosis of prostatic adenocarcinoma]. |
AgNORs, PH, TSC |
| 50 |
1995 |
Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. |
BM |
| 51 |
1994 |
Quantitative characterization of the frequency and location of cell proliferation and death in prostate pathology. |
ABs, CET, NP, PCNA, PIN |
|
A Search Service for Abbreviation / Long Form
